Consistent with the concept that autoimmunity and cancer rejection might represent different facets of the same phenomenon, we observed that polymorphisms protecting against the susceptibility to develop SLE[12,13], such as the IRF5 rs10954213 GG genotype, were significantly more prevalent among patients who did not respond to adoptive TIL therapy. Here, IRF5 is linked to cancer.